Indivior PLC — Board/Management Information 2018

Apr 11, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6272K

Indivior PLC

11 April 2018

Indivior PLC (the 'Company')

Indivior PLC confirms that Mr Daniel Tassé, Senior Independent Director, was appointed as an independent director of HLS Therapeutics Inc., a specialty pharmaceutical company listed on the TSX Venture Exchange, with effect from March 14, 2018.

This announcement is made in accordance with Listing Rule 9.6.14.

Kathryn Hudson

Company Secretary

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNFKDDKPBKDDQD